Paragon Capital Management Ltd reduced its holdings in shares of Colgate-Palmolive (NYSE:CL) by 5.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,968 shares of the company’s stock after selling 1,200 shares during the quarter. Colgate-Palmolive accounts for about 0.6% of Paragon Capital Management Ltd’s holdings, making the stock its 18th biggest position. Paragon Capital Management Ltd’s holdings in Colgate-Palmolive were worth $1,308,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Genesis Asset Managers LLP bought a new position in shares of Colgate-Palmolive during the third quarter valued at about $184,557,000. Bank of New York Mellon Corp lifted its position in shares of Colgate-Palmolive by 8.6% during the second quarter. Bank of New York Mellon Corp now owns 20,135,385 shares of the company’s stock valued at $1,304,974,000 after purchasing an additional 1,596,825 shares in the last quarter. Morgan Stanley lifted its position in shares of Colgate-Palmolive by 15.0% during the third quarter. Morgan Stanley now owns 7,212,524 shares of the company’s stock valued at $482,879,000 after purchasing an additional 941,008 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Colgate-Palmolive by 376.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,502 shares of the company’s stock valued at $69,073,000 after purchasing an additional 917,012 shares in the last quarter. Finally, Vanguard Group Inc lifted its position in shares of Colgate-Palmolive by 1.0% during the third quarter. Vanguard Group Inc now owns 73,520,894 shares of the company’s stock valued at $4,922,224,000 after purchasing an additional 734,860 shares in the last quarter. Hedge funds and other institutional investors own 74.47% of the company’s stock.
In other Colgate-Palmolive news, Director John T. Cahill sold 5,780 shares of Colgate-Palmolive stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $64.46, for a total value of $372,578.80. Following the sale, the director now owns 27,820 shares of the company’s stock, valued at $1,793,277.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.02% of the company’s stock.
Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 25th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.78 billion. Colgate-Palmolive had a net margin of 15.44% and a return on equity of 25,268.29%. The company’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. On average, equities analysts forecast that Colgate-Palmolive will post 2.83 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Wednesday, January 23rd will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 2.58%. The ex-dividend date of this dividend is Tuesday, January 22nd. Colgate-Palmolive’s dividend payout ratio is 56.57%.
A number of research analysts recently weighed in on CL shares. Wells Fargo & Co dropped their price target on shares of Colgate-Palmolive from $64.00 to $62.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 17th. UBS Group set a $71.00 price target on shares of Colgate-Palmolive and gave the company a “buy” rating in a research report on Wednesday, October 17th. SunTrust Banks lowered shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and dropped their price target for the company from $80.00 to $65.00 in a research report on Friday, October 26th. JPMorgan Chase & Co. lowered shares of Colgate-Palmolive from a “neutral” rating to an “underweight” rating and dropped their price target for the company from $61.00 to $54.00 in a research report on Monday, October 29th. Finally, Citigroup dropped their price target on shares of Colgate-Palmolive from $68.00 to $63.00 and set a “hold” rating on the stock in a research report on Monday, October 29th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company. Colgate-Palmolive currently has an average rating of “Hold” and a consensus price target of $65.00.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Further Reading: Marijuana Stocks
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.